莎普爱思品牌怎么样 申请店铺

更新时间:2024-10-28
莎普爱思是哪个国家的品牌?「莎普爱思」是 浙江莎普爱思药业股份有限公司 旗下著名品牌。该品牌发源于浙江,由创始人陈德康在2000-07-17期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
莎普爱思怎么样

公司自1978年建厂以来,经历了从“国营浙江平湖制药厂”转制成“浙江平湖制药厂(股份合作)”到“浙江平湖莎普爱思制药有限公司”,再到“浙江莎普爱思制药有限公司”,最终于2008年12月15日更名为“浙江莎普爱思药业股份有限公司”,目前注册资金为4900万元人民币。

公司作为一家专业从事药品研发、生产、经营的综合性制药企业,先后被列为“国家高新技术企业”、“浙江省百家最具投资价值企业”、“浙江省千家成长之星企业”、“浙江省级企业技术中心”、“省级高新技术研究开发中心”、“浙江省标准创新型企业”、“嘉兴市重点企业技术创新团队”、“院士专家工作站”等多项荣誉称号。

目前公司拥有大容量注射剂(玻璃瓶、塑料瓶和多层共挤膜袋)、口服溶液剂、滴眼剂、片剂(含头孢菌素类)、硬胶囊剂(含头孢菌素类)、栓剂、颗粒剂(含头孢菌素类)、干混悬剂(含头孢菌素类)、冲洗剂共10个剂型,近百种规格的产品批准文号。抗白内障新药“莎普爱思”滴眼液和抗青光眼新药“达靓”滴眼液被列入“国家火炬计划项目”。“莎普爱思”滴眼液还荣获国家重点科技攻关项目、国家重点新产品、浙江省名牌产品等多个称号,是国内第一个国家二类眼科专科新药。

几十年来,公司凭着优质的产品,良好的信誉,在市场竞争日益激烈的情况下,赢得了市场,产品销往全国各地,取得了良好的经济效益。近年来公司的产品销量与销售额都呈现出逐年增涨的态势,是平湖市重点扶持的股改上市企业。

在竞争激烈的医药市场中,我公司始终坚持科技兴业、加强管理、保证质量,不断推出各种自主研发的新产品。公司秉承“科技创新、求是进取、优质高效、和谐健康”的企业精神,不断寻求创新与突破,逐步使公司成为现代化、高科技制药企业。

莎普爱思的未来将坚持以市场为导向,发展为主题,科技创新为核心。以保护和增进人民健康、提高人民福祉为目标。我们确信莎普爱思的无限“关爱”会遍及中国,走向世界。

Since its establishment in 1978, the company has gone through the transformation from "state-owned Zhejiang Pinghu pharmaceutical factory" to "Zhejiang Pinghu pharmaceutical factory (joint stock cooperation)" to "Zhejiang Pinghu sapais Pharmaceutical Co., Ltd." and then to "Zhejiang sapais Pharmaceutical Co., Ltd." and finally changed its name to "Zhejiang sapais pharmaceutical Co., Ltd." on December 15, 2008, with the current registered capital of 49 million yuan RMB. As a comprehensive pharmaceutical enterprise specializing in drug R & D, production and operation, the company has been listed as "national high-tech enterprise", "one hundred enterprises with the most investment value in Zhejiang Province", "one thousand growth star enterprises in Zhejiang Province", "Zhejiang provincial enterprise technology center", "provincial high-tech research and development center", "Zhejiang standard innovation enterprise" "Jiaxing key enterprise technology innovation team", "academician expert workstation" and other honorary titles. At present, the company has 10 dosage forms of large capacity injection (glass bottles, plastic bottles and multi-layer coextrusion film bags), oral solution, eye drops, tablets (including cephalosporins), hard capsules (including cephalosporins), suppositories, granules (including cephalosporins), dry suspension (including cephalosporins), washing agents, and approval numbers of nearly 100 specifications of products. The new anti cataract drug "sapais" eye drops and the new anti glaucoma drug "Daliang" eye drops are listed in the "National Torch Program project". "Saps eye drops" also won the titles of national key scientific and technological research projects, national key new products, Zhejiang famous brand products, etc., and is the first national class II ophthalmic specialty new drug in China. In the past few decades, with its high quality products and good reputation, the company has won the market and sold its products to all parts of the country under the increasingly fierce market competition, and achieved good economic benefits. In recent years, the sales volume and sales volume of the company have been increasing year by year. It is a listed company supported by Pinghu City. In the highly competitive pharmaceutical market, our company always adheres to the development of science and technology, strengthening management, ensuring quality, and constantly launches various new products independently researched and developed. The company adheres to the enterprise spirit of "scientific and technological innovation, truth-seeking and enterprising, high-quality and efficient, harmonious and healthy", constantly seeks innovation and breakthrough, and gradually makes the company become a modern, high-tech pharmaceutical enterprise. In the future, SAPS will adhere to the market-oriented, development oriented theme and technological innovation as the core. With the goal of protecting and promoting people's health and improving people's well-being. We are sure that the infinite "love" of sapeus will spread all over China and go to the world.

本文链接: https://brand.waitui.com/a5a71ec58.html 联系电话:057385013183

千城特选小程序码

7×24h 快讯

上交所终止如鲲新材科创板发行上市审核

36氪获悉,据上交所,因上海如鲲新材料股份有限公司及其保荐人东方证券股份有限公司撤回发行上市申请,上交所终止其科创板发行上市审核。

30分钟前

万华化学:第三季度营收505.37亿元,同比增长12.48%

36氪获悉,万华化学发布第三季财报。财报显示,第三季度营收为505.37亿元,同比增长12.48%;净利润为29.19亿元,同比下降29.41%。前三季度营收为1476.04亿元,同比增长11.35%;净利润为110.93亿元,同比下降12.67%。

30分钟前

新安股份:控股子公司拟1.9亿元收购传化嘉易100%股东权益

36氪获悉,新安股份公告,公司控股子公司华洋化工拟出资1.9亿元,收购传化智联持有的传化嘉易100%股东权益。本次收购传化嘉易100%股权旨在解决制约控股子公司华洋化工发展战略的瓶颈问题,有利于其扩大生产规模,升级产品工艺,增强新产品的研发生产能力。本次交易构成关联交易,交易对方传化智联为公司控股股东传化集团的控股子公司。

30分钟前

南网储能:第三季度营业收入45.19亿元,同比增长11.12%

36氪获悉,南网储能发布2024年第三季度财报。报告显示,公司前三季度实现营业收入45.19亿元,同比增长11.12%;归属于上市公司股东的净利润10.45亿元,同比增长27.62%。第三季度实现营业收入16.08亿元,同比增长33.33%;归属于上市公司股东的净利润4.19亿元,同比增长231.49%。

30分钟前

上周无新增IPO申报企业

36氪获悉,上周(10月21日—10月27日)无新增IPO申报企业。截至10月27日,今年新增IPO申报企业35家。截至10月27日,各板块在审企业共277家。其中上交所77家(主板52家,科创板25家),深交所111家(主板36家,创业板75家),北交所89家。

30分钟前

本页详细列出关于莎普爱思的品牌信息,含品牌所属公司介绍,莎普爱思所处行业的品牌地位及优势。
咨询